|
Name |
alpha-Agarofuran
|
| Molecular Formula | C15H24O | |
| IUPAC Name* |
(1R,6S,9R)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.01,6]dodec-2-ene
|
|
| SMILES |
CC1=CCC[C@@]2([C@]13C[C@@H](CC2)C(O3)(C)C)C
|
|
| InChI |
InChI=1S/C15H24O/c1-11-6-5-8-14(4)9-7-12-10-15(11,14)16-13(12,2)3/h6,12H,5,7-10H2,1-4H3/t12-,14+,15+/m1/s1
|
|
| InChIKey |
ZLQADKTVJQXDIG-SNPRPXQTSA-N
|
|
| Synonyms |
alpha-Agarofuran; SCHEMBL17627627; (1R,6S,9R)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.01,6]dodec-2-ene; 5956-12-7
|
|
| CAS | NA | |
| PubChem CID | 10857022 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 220.35 | ALogp: | 3.0 |
| HBD: | 0 | HBA: | 1 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 9.2 | Aromatic Rings: | 3 |
| Heavy Atoms: | 16 | QED Weighted: | 0.538 |
| Caco-2 Permeability: | -4.582 | MDCK Permeability: | 0.00001770 |
| Pgp-inhibitor: | 0.023 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.057 |
| 30% Bioavailability (F30%): | 0.149 |
| Blood-Brain-Barrier Penetration (BBB): | 0.138 | Plasma Protein Binding (PPB): | 96.56% |
| Volume Distribution (VD): | 1.566 | Fu: | 2.17% |
| CYP1A2-inhibitor: | 0.145 | CYP1A2-substrate: | 0.816 |
| CYP2C19-inhibitor: | 0.277 | CYP2C19-substrate: | 0.94 |
| CYP2C9-inhibitor: | 0.313 | CYP2C9-substrate: | 0.159 |
| CYP2D6-inhibitor: | 0.028 | CYP2D6-substrate: | 0.275 |
| CYP3A4-inhibitor: | 0.334 | CYP3A4-substrate: | 0.702 |
| Clearance (CL): | 9.814 | Half-life (T1/2): | 0.161 |
| hERG Blockers: | 0.033 | Human Hepatotoxicity (H-HT): | 0.827 |
| Drug-inuced Liver Injury (DILI): | 0.053 | AMES Toxicity: | 0.008 |
| Rat Oral Acute Toxicity: | 0.023 | Maximum Recommended Daily Dose: | 0.367 |
| Skin Sensitization: | 0.468 | Carcinogencity: | 0.529 |
| Eye Corrosion: | 0.345 | Eye Irritation: | 0.891 |
| Respiratory Toxicity: | 0.915 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002337 | ![]() |
0.600 | D0H1QY | ![]() |
0.304 | ||
| ENC003049 | ![]() |
0.492 | D0U3GL | ![]() |
0.250 | ||
| ENC001810 | ![]() |
0.492 | D0V8HA | ![]() |
0.246 | ||
| ENC002112 | ![]() |
0.466 | D0L2LS | ![]() |
0.239 | ||
| ENC000085 | ![]() |
0.423 | D0Z1XD | ![]() |
0.235 | ||
| ENC005519 | ![]() |
0.423 | D08QKJ | ![]() |
0.231 | ||
| ENC002143 | ![]() |
0.393 | D04GJN | ![]() |
0.231 | ||
| ENC001080 | ![]() |
0.393 | D0Q6NZ | ![]() |
0.222 | ||
| ENC001135 | ![]() |
0.371 | D0A2AJ | ![]() |
0.221 | ||
| ENC001077 | ![]() |
0.338 | D06IIB | ![]() |
0.219 | ||